Thursday, July 29, 2010

BWI: Centaur Pharmaceuticals In-Licenses Herpes Drug Sorivudine from aRigen Pharmaceuticals Japan

Press release from Business Wire India
Source: Centaur Pharmaceuticals Private Limited
Thursday, July 29, 2010 06:00 PM IST (12:30 PM GMT)
Editors: General: Consumer interest; Business: Advertising, PR & marketing, Healthcare, biotechnology & pharmaceutical; Healthcare
Centaur Pharmaceuticals In-Licenses Herpes Drug Sorivudine from aRigen Pharmaceuticals Japan

Mumbai, Maharashtra, India, Thursday, July 29, 2010 -- (Business Wire India) -- Centaur has in-licensed the development and distribution rights for Sorivudine, a topical antiviral drug from aRigen, for India and neighbouring countries. Centaur will soon approach the Drugs Controller General, India (DCGI) for permission for Phase II and Phase III trials and for marketing rights in India. Sorivudine is a local application, for Herpes Zoster, which will be introduced for the first time in India, by 2013.

aRigen's President & CEO, Dr Gensuke Tokoro, says "aRigen Pharmaceuticals is a drug discovery and development biotech company in Japan (Tokyo) with a commitment to discovering breakthrough pharmaceutical seeds discovered in Japan, and developing innovative pharmaceutical products for the entire global population."

Commenting on the deal, Centaur's Managing Director, Mr SD Sawant, said, "Centaur Pharmaceuticals, ranks among India's few, fully integrated pharmaceutical firms. We have built 4 building blocks to drive future growth- formulations, API, contract manufacturing and clinical research. Our strategy is to ink similar in-licensing agreements with the world's leading drug discovery and development players like aRigen, and derive synergies by leveraging our proficiencies across the pharmaceutical value chain."

Centaur had earlier received the development rights for the new chemical entity (NCE), DPOCL (Diperoxochloric Acid) solution, for Diabetic Foot Ulcer from Cyto Tools AG, Germany. Centaur's clinical research division, LifeSan Clinical Research, have successfully conducted Phase II trials in India for DPOCL, and have applied for permission for Phase III to DCGI. DPOCL will be introduced for the first time in India, by 2012.

About aRigen Pharmaceuticals, Inc (

aRigen was established in Tokyo, Japan, in 2001. aRigen is uniquely positioned as a leading R&D biotech company in Japan in anti-infective products, with six key products rapidly advancing in the clinical development. aRigen also specialises in antibacterials, antivirals and antiprotozoals.

About Centaur Pharmaceuticals Private Limited (

Centaur was established in Mumbai, India, in 1978. Centaur ranks among India's Top 50 pharmaceutical players. In India, Centaur brands are leaders in 6 therapy segments, including the anticold segment, with Sinarest. Centaur is India's largest manufacturer and exporter of psychotropic API, with an USFDA approved facility. Centaur is strategically positioned in the contract manufacturing space with its UKMHRA and TGA, Australia, approved formulations facility in Pune. Centaur has built competencies in clinical research space with capabilities to conduct BA-BE studies and phase II/III/IV trials.

To view photographs kindly click on the links below:

Centaur Pharmaceuticals Managing Director, Mr SD Sawant and aRigen's President & CEO, Dr Gensuke Tokoro

Centaur House

For picture(s)/data to illustrate this release click below:

Dr Amit Rangnekar General Manager (Business Development), Centaur Pharmaceuticals Private Limited, +91 98200 27699 / +91 (22) 6649 9132,


If you wish to change your Business Wire India selection please click on this link and use your personal username and password to login.

Submit your press release at

No comments:

Post a Comment